SCHEMBL4776447

SCHEMBL4776447

Cc1nc2c(C(=O)NCC(N)=O)cnn2c(C)c1Cc1cccc(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RUVBL1 Q9Y265 1/20 0.59
LMNA P02545 9/20 0.56
TP53 P04637 9/20 0.56
KDM4E B2RXH2 6/20 0.56
ALDH1A1 P00352 6/20 0.56
HPGD P15428 5/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
MAPT P10636 3/20 0.56
HSD17B10 Q99714 2/20 0.56
MEN1 O00255 2/20 0.56
HTT P42858 2/20 0.56
KMT2A Q03164 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
USP2 O75604 1/20 0.56
TSHR P16473 1/20 0.56
ALOX12 P18054 1/20 0.56
MAPK1 P28482 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
CCR1 P32246 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4725426 0.87 RUVBL1 (0.57) RUVBL1LMNATP53KDM4EALDH1A1
SCHEMBL4725598 0.86 LMNA (0.59) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL4776338 0.86 HSD17B10 (0.64) RUVBL1LMNATP53KDM4EALDH1A1
SCHEMBL4781535 0.85 KDM4E (0.58) RUVBL1LMNATP53KDM4EALDH1A1
SCHEMBL4794519 0.81 LMNA (0.53) RUVBL1LMNATP53KDM4EALDH1A1
SCHEMBL4725963 0.79 LMNA (0.69) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL22796420 0.77 RUVBL1 (0.47) RUVBL1LMNATP53KDM4EALDH1A1
SCHEMBL4780599 0.77 LMNA (0.70) LMNATP53KDM4EALDH1A1HPGD
SCHEMBL22796771 0.77 RUVBL1 (0.52) RUVBL1LMNATP53KDM4EALDH1A1
SCHEMBL22796423 0.77 RUVBL1 (0.47) RUVBL1LMNATP53KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080221129-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-09-11 US claimed
WO-2008003753-A1 PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO claimed
US-20080221129-A1 New compounds BIOVITRUM AB (PUBL) (SE) 2008-09-11 US disclosed
WO-2008003753-A1 PYRAZOLO [1,5-A] PYRIMIDINE ANALOGS FOR USE AS INHIBITORS OF STEAROYL-COA DESATURASE (SCD) ACTIVITY BIOVITRUM AB (PUBL) (SE) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221129-A1 New compounds SCD, SCD5, FASN RUVBL1 440/4885LMNA 2075/4885TP53 1572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.